Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Pricing of Marketed Public Offering of Units

<< Previous

Bullboard Posts

Next >>

Comment by 13X2413on Dec 14, 2021 6:21pm

127 Views

Post# 34230815

RE:Pricing of Marketed Public Offering of Units

I'm assuming they had to lower it because of where stock price is. If they had something good in the pipe, they would have released some news, kept the stock price up and the offering at a higher amount.

Another case of no news is bad news.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing